Intermittent theta burst stimulation for negative symptoms in schizophrenia patients with moderate to severe cognitive impairment: A randomized controlled trial
Psychiatry and Clinical Neurosciences · 2025
DOI: 10.1111/pcn.13779 ↗At a glance
Randomisierte kontrollierte Studie in Psychiatry and Clinical Neurosciences, 2025. Written by Jing Li and 5 co-authors. Institution: Mental Health Center, West China Hospital, Sichuan University, Chengdu, China. Major MEDLINE topics: Cognitive Dysfunction, Outcome Assessment, Health Care, Prefrontal Cortex, Schizophrenia. Cited 8 times so far (Crossref); 48 references. Funded by: 1 3 5 project for disciplines of excellence, West China Hospital, Sichuan University.
Abstract (original language)
Aims
This study aims to assess the therapeutic effects of intermittent theta burst stimulation (iTBS) targeting the bilateral dorsomedial prefrontal cortex (DMPFC) on negative symptoms in patients with schizophrenia, utilizing functional near‐infrared spectroscopy for evaluation.
Methods
Thirty‐five schizophrenia patients with negative symptoms and moderate to severe cognitive impairment were randomly assigned to a treatment group ( n = 18) or a control group ( n = 17). The treatment group received iTBS via bilateral DMPFC. Negative symptoms, cognitive function, emotional state, and social function were assessed using Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Montreal Cognitive Assessment (MoCA), Calgary Depression Scale for Schizophrenia (CDSS), and Social Dysfunction Screening Questionnaire (SDSS) scales at pretreatment, posttreatment, and follow‐up at 4, 8, and 12 weeks. Brain activation in regions of interest (ROIs) was evaluated through verbal fluency tasks.
Results
Prior to treatment there was no significant difference in the two groups. After 20 iTBS sessions, a significant difference was observed in SANS total score, its related subscales, PANSS total score, and PANSS‐negative symptoms (all P < 0.05). The group‐by‐time interaction showed statistical significance, indicating improvements in negative symptoms and related dimensions over time, with therapeutic effects persisting for at least 8 weeks posttreatment. Prior to treatment, there were no significant differences in activation across all ROIs between the two groups. Posttreatment, the activation of right inferior frontal gyrus ( t = 2.19, P = 0.036) and right frontal eye field ( t = 2.14, P = 0.04) in the treatment group was significantly higher than in the control group. Conclusions iTBS stimulation of bilateral DMPFC demonstrates therapeutic effects in improving negative symptoms in schizophrenia patients, and this treatment approach has the potential to enhance activation within the prefrontal cortex.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Mental Health Center, West China Hospital, Sichuan University, Chengdu, China.
- Psychiatry Department, Jinxin Mental Hospital, Chengdu, China.
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China.
ORCID profiles: Jing Li
Funding
- 1 3 5 project for disciplines of excellence, West China Hospital, Sichuan University
Cite
APA
Li, J., Jiang, D., Huang, X., Wang, X., Xia, T., & Zhang, W. (2025). Intermittent theta burst stimulation for negative symptoms in schizophrenia patients with moderate to severe cognitive impairment: A randomized controlled trial. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13779
Vancouver
Li J, Jiang D, Huang X, Wang X, Xia T, Zhang W. Intermittent theta burst stimulation for negative symptoms in schizophrenia patients with moderate to severe cognitive impairment: A randomized controlled trial. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13779
BibTeX
@article{Li2025,
author = {Li, Jing and Jiang, Dan and Huang, Xingyu and Wang, Xiao and Xia, Tingting and Zhang, Wei},
title = {Intermittent theta burst stimulation for negative symptoms in schizophrenia patients with moderate to severe cognitive impairment: A randomized controlled trial},
journal = {Psychiatry and Clinical Neurosciences},
year = {2025},
doi = {10.1111/pcn.13779}
}
EUVIMED